ALFA FinderNSE filing, NSE: TAPIFRUIT. Summary written from the filing by ALFA Finder's alert engine.
Tapi Fruit Processing Ltd: key numbers
- Share price
- ₹41.80
- Market cap
- ₹17.98 Cr
- Revenue (annual)
- ₹28.53 Cr
- Net profit (annual)
- ₹-1.68 Cr
- P/E (TTM)
- -10.7×Sector 41.3×
- Promoter holding
- 65.72%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Tapi Fruit Processing Ltd
All →Tapi Fruit Processing H1 FY27 Results: Net Loss of ₹1 Cr, Loss Widens
Tapi Fruit Processing Ltd reported revenue from operations of ₹14.9 Cr (+20.2% YoY) and a net loss of ₹1 Cr for H1 FY27.
- Key figure
- Net loss ₹1 Cr
Tapi Fruit Processing Board Meeting Date
Tapi Fruit Processing will hold a board meeting on November 3, 2026 to consider unaudited standalone and consolidated half-yearly results for September 2026. Trading window closes from October 1 to November 5, 2026.
Tapi Fruit Processing Other Announcement
Tapi Fruit Processing Limited filed a certificate confirming no dematerialization or rematerialization requests were received from shareholders for the quarter ended September 30, 2026.
Tapi Fruit Processing Annual General Meeting
Tapi Fruit Processing Limited held its 8th Annual General Meeting on September 26, 2026. The meeting covered adoption of financial statements and re-appointment of directors.
Tapi Fruit Processing Other Announcement
Tapi Fruit Processing Limited notified shareholders without registered email addresses about accessing the Annual Report 2025-26 and the upcoming 8th AGM via web links.
Tapi Fruit Processing Annual General Meeting
Tapi Fruit Processing Limited will hold its 8th Annual General Meeting on September 26, 2026. Shareholders will consider re-appointing directors and approving related party transactions worth ₹30 Crore.
- Value
- ₹30.00 Cr
Other product launch announcements
All →Jeena Sikho Lifecare Product Launch
Jeena Sikho Lifecare launched ten new Ayurvedic healthcare products in the domestic market on November 11, 2026. The filing gives product-wise details under SEBI product-launch disclosure rules.
HCL Technologies Product Launch
HCLTech launched a pre-configured semiconductor PLM solution built on PTC Windchill, developed in collaboration with PTC. The release states no contract value or deal size, and the launch is a new product offering.
Morepen Laboratories Product Launch
Morepen launched Desloratadine Tablets USP 5 mg, its first US prescription generic, through subsidiary Morepen Bio Inc. It also filed a Sitagliptin ANDA with the US FDA.
AstraZeneca Pharma India Product Launch
AstraZeneca Pharma India will launch Datverzo, Datopotamab Deruxtecan, in India in November 2026. The drug holds DCGI import and market permission for HR-positive, HER2-negative breast cancer.
Raama Finance Product Launch
Raama Finance launched 'Rupya Lelo', a digital lending platform offering instant personal loans, on October 6, 2026. The product is available only in India, and no loan amount or financial figure is disclosed.
Puravankara Product Launch
Puravankara will launch the residential project Purva Cityspire Phases 1, 2 and 3 in Ernakulam on 15 November 2026. The project is RERA-registered and is being developed by two wholly owned subsidiaries.